SCYNEXIS, Inc. Banner Image

SCYNEXIS, Inc. has reached its limit for free report views

Work for SCYNEXIS, Inc.? Upgrade Your Profile and unlock all your annual reports.


  • Ticker SCYX
    Exchange NASDAQ More
  • Industry Drug Manufacturers - Other More
  • Sector Healthcare More
SCYNEXIS, Inc. Logo Image
  • 11-50 Employees
  • Based in Jersey City, New Jersey
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Their lead candidate, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class, in late stageMore development for multiple indications, ranging from vaginal yeast infections to life-threatening fungal infections in hospitalized patients. The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization.
4.8 / 5.0 (252)

SCYNEXIS, Inc. reports have an aggregate usefulness score of 4.8 based on 252 reviews.


Most Recent Annual Report

MOST RECENT 2022 Annual Report and Form 10K

Report Locked. SCYNEXIS, Inc. has reached its limit for free report views.

Older/Archived Annual Reports

SCYNEXIS, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!